Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Chen LT 1 , Martinelli E 2 , Cheng AL 3 , Pentheroudakis G 4 , Qin S 5 , Bhattacharyya GS 6 Show all authors , Ikeda M 7 , Lim HY 8 , Ho GF 9 , Choo SP 10 , Ren Z 11 , Malhotra H 12 , Ueno M 13 , Ryoo BY 14 , Kiang TC 15 , Tai D 16 , Vogel A 17 , Cervantes A 18 , Lu SN 19 , Yen CJ 20 , Huang YH 21 , Chen SC 22 , Hsu C 23 , Shen YC 24 , Tabernero J 25 , Yen Y 26 , Hsu CH 27 , Yoshino T 7 , Douillard JY 28

Affiliations 

  • 1 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan; Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: leochen@nhri.org.tw
  • 2 Department of Clinical and Experimental Medicine 'F Magrassi' - Medical Oncology, Università degli Studi della Campania L Vanvitelli, Naples, Italy
  • 3 Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
  • 4 Department of Medical Oncology, University of Ioannina, Ioannina, Greece
  • 5 Chinese PLA Cancer Center, Jinling Hospital, Nanjing, China
  • 6 Salt Lake City Medical Center, Kolkata, India
  • 7 Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Japan
  • 8 Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea
  • 9 Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 10 Curie Oncology, Singapore; National Cancer Centre Singapore, Singapore, Singapore
  • 11 Zhongshan Hospital, Fudan University, Shanghai, China
  • 12 Department of Medical Oncology, Sri Ram Cancer Center, Mahatma Gandhi Medical College Hospital, Jaipur, India
  • 13 Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
  • 14 Department of Oncology, Asan Medical Center University of Ulsan College of Medicine, Seoul, South Korea
  • 15 Hospital Umum Sarawak, Kuching, Sarawak, Malaysia
  • 16 Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
  • 17 Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
  • 18 CIBERONC, Department of Medical Oncology, Institute of Health Research, INCLIVIA, University of Valencia, Valencia, Spain
  • 19 Division of Hepato-Gastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
  • 20 Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan
  • 21 Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
  • 22 Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
  • 23 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
  • 24 Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
  • 25 Medical Oncology Department, Vall d' Hebron University Hospital and Institute of Oncology (VHIO), UVic, IOB-Quiron, Barcelona, Spain
  • 26 Taipei Medical University, Taipei, Taiwan
  • 27 Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
  • 28 ESMO, Lugano, Switzerland
Ann Oncol, 2020 03;31(3):334-351.
PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications